110 related articles for article (PubMed ID: 37648468)
21. Influence of sarcopenia as defined by EWGSOP2 on complications after pancreaticoduodenectomy and on the prognosis of pancreatic head cancer: A prospective cohort study.
Aoki Y; Furukawa K; Suzuki D; Takayashiki T; Kuboki S; Takano S; Kawasaki Y; Shiko Y; Ohtsuka M
Nutrition; 2022; 99-100():111660. PubMed ID: 35576875
[TBL] [Abstract][Full Text] [Related]
22. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer.
Shimura M; Mizuma M; Motoi F; Kusaka A; Aoki S; Iseki M; Inoue K; Douchi D; Nakayama S; Miura T; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Kamei T; Unno M
Pancreatology; 2023 Jan; 23(1):65-72. PubMed ID: 36473785
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
24. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer.
Abe K; Furukawa K; Okamoto T; Matsumoto M; Futagawa Y; Haruki K; Shirai Y; Ikegami T
Int J Clin Oncol; 2021 Oct; 26(10):1929-1937. PubMed ID: 34232427
[TBL] [Abstract][Full Text] [Related]
25. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcomes of Gastric Cancer Patients with Preoperative Sarcopenia.
Kawamura T; Makuuchi R; Tokunaga M; Tanizawa Y; Bando E; Yasui H; Aoyama T; Inano T; Terashima M
Ann Surg Oncol; 2018 Jun; 25(6):1625-1632. PubMed ID: 29633095
[TBL] [Abstract][Full Text] [Related]
27. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
28. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer.
Nakajima H; Yamaguchi J; Takami H; Hayashi M; Kodera Y; Nishida Y; Watanabe N; Onoe S; Mizuno T; Yokoyama Y; Ebata T
Int J Clin Oncol; 2023 May; 28(5):688-697. PubMed ID: 36872415
[TBL] [Abstract][Full Text] [Related]
29. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(4):604-611. PubMed ID: 33479765
[TBL] [Abstract][Full Text] [Related]
30. The Surgical Apgar Score Is an Independent Prognostic Factor in Patients with Pancreatic Cancer Undergoing Pancreatoduodenectomy Followed by Adjuvant Chemotherapy.
Aoyama T; Kazama K; Murakawa M; Atsumi Y; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Anticancer Res; 2016 May; 36(5):2497-503. PubMed ID: 27127164
[TBL] [Abstract][Full Text] [Related]
31. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy.
Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
J Gastroenterol; 2021 Jan; 56(1):101-113. PubMed ID: 33094352
[TBL] [Abstract][Full Text] [Related]
32. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
[TBL] [Abstract][Full Text] [Related]
35. Development and Validation of Cutoff Value for Reduced Muscle Mass for GLIM Criteria in Patients with Gastrointestinal and Hepatobiliary-Pancreatic Cancers.
Takimoto M; Yasui-Yamada S; Nasu N; Kagiya N; Aotani N; Kurokawa Y; Tani-Suzuki Y; Kashihara H; Saito Y; Nishi M; Shimada M; Hamada Y
Nutrients; 2022 Feb; 14(5):. PubMed ID: 35267918
[TBL] [Abstract][Full Text] [Related]
36. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
37. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
[TBL] [Abstract][Full Text] [Related]
39. Skeletal Muscle Loss and Octogenarian Status Are Associated with S-1 Adjuvant Therapy Discontinuation and Poor Prognosis after Pancreatectomy.
Tsukagoshi M; Harimoto N; Araki K; Kubo N; Watanabe A; Igarashi T; Ishii N; Yamanaka T; Hagiwara K; Hoshino K; Muranushi R; Yajima T; Shirabe K
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439259
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
